X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Quince gains right for EryDel's Phase 3 lead asset, EryDex (dexamethasone sodium phosphate), targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia (A-T), which currently has no approved treatments.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Genetic Disease Product Name: EryDex
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: EryDel
Deal Size: $485.0 million Upfront Cash: $485.0 million
Deal Type: Acquisition October 23, 2023
Details:
EryDex (dexamethasone sodium phosphate) utilizes a unique drug/device combination that enables a fully automated process at the point of patient care for the autologous intracellular drug encapsulation for the Treatment of Ataxia-Telangiectasia.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Genetic Disease Product Name: EryDex
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Through the acquisition, Quince gains right for EryDel's Phase 3 lead asset, EryDex (dexamethasone sodium phosphate), targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia (A-T), which currently has no approved treatments.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Genetic Disease Product Name: EryDex
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: EryDel
Deal Size: $485.0 million Upfront Cash: $485.0 million
Deal Type: Acquisition July 24, 2023
Details:
Under the agreement, Lighthouse gains exclusive rights to develop, manufacture, and commercialize Quince’s legacy protease inhibitor portfolio including, COR588, COR388, COR852, and COR803 globally.
Lead Product(s): COR588
Therapeutic Area: Neurology Product Name: COR588
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Lighthouse Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Divestment January 30, 2023
Details:
In preclinical studies, Quince observed a decrease in fracture healing time by 50% in NOV004 treated groups. Additionally, bone deposition and max load doubled and the force required to refracture the bones increased more than two-fold in mouse models.
Lead Product(s): NOV004
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: NOV004
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
In preclinical studies, NOV004 concentrated at spinal fusion sites to demonstrate accelerated repair in treated animals which resulted in improved blinded radiographic fusion scores compared to animals treated with current standard of care, bone morphogenic protein-2.
Lead Product(s): NOV004
Therapeutic Area: Genetic Disease Product Name: NOV004
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
NOV004 was prepared by synthesizing an abaloparatide-like peptide conjugated to a hydroxyapatite-homing acidic oligopeptide to create a high affinity to bone fractures.
Lead Product(s): NOV004
Therapeutic Area: Genetic Disease Product Name: NOV004
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture
Lead Product(s): NOV004
Therapeutic Area: Genetic Disease Product Name: NOV004
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
COR588 is a selective, oral small-molecule inhibitor of lysine gingipains, protease virulence factors secreted by P. gingivalis, and is being developed for the potential treatment of patients with Alzheimer’s disease.
Lead Product(s): COR588
Therapeutic Area: Neurology Product Name: COR588
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral replication of SARS-CoV-2.
Lead Product(s): COR803
Therapeutic Area: Infections and Infectious Diseases Product Name: COR803
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
